

May 4, 2018

To,
Mr. Sandeep Dhamal
Assistant Manager - Listing Compliance,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.
Ref: Scrip Name: GLENMARK

Dear Sir,

Sub:- News Clarification

This is with reference to your email dated May 4, 2018, seeking clarification on the news appearing in today's newspaper regarding clinical trial. In this regard, please find our statement below:

Glenmark has been conducting clinical trials in India and around the world since many years. Patient safety and regulatory compliance are of utmost importance to us. The Malpani Hospital in Jaipur is one of the many sites that had recently initiated Phase II clinical trial for Glenmark's molecule GRC 27864 in patients with moderate osteoarthritis pain. Malpani Hospital is a CDSCO-approved site for clinical trials and it has been conducting trials for many companies, including multinationals, over the past several years. As soon as the Company became aware of the alleged irregularities at Malpani Hospital, the trial at the site were immediately suspended in the interest of patient safety. Further, we would like to state that we have all the requisite approvals in place for the trial at the site and have already submitted all supporting documents of the approvals to the regulator. We have received the show cause notice pertaining to monitoring of the clinical trial at Malpani Hospital and will respond to it within the stipulated time frame.

This development does not have any material impact on the Company.

We have been proactive in informing the Exchange about events of the Company and with regards to the above mentioned clinical trial, kindly refer to the press release sent to the Exchange on January 15, 2018 about DCGI-approval for initiation of Phase II study for GRC 27864.

Requesting you to kindly take the same on record.

Thanking You.

Yours faithfully,
For Glenmark Pharmaceuticals Ltd.



Harish Kuber
Company Secretary & Compliance Officer